Efficacy and Safety of Weekly Alendronate Plus Vitamin D3 5600 IU versus Weekly Alendronate Alone in Korean Osteoporotic Women: 16-Week Randomized Trial
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D]. This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D3 (ALN/D5600) to alendronate 70 mg without additional vit-D (ALN) on the percent of patients with vit-D insufficiency [25(OH)D <15 ng/mL, primary endpoint]and serum parathyroid hormone (PTH, secondary endpoint) levels in postmenopausal,osteoporotic Korean women. Neuromuscular function was also measured. A total of 268 subjects were randomized. Overall, 35% of patients had vit-D insufficiency at baseline. After 16-weeks, there were fewer patients with vit-D insufficiencyin the ALN/D5600 group (1.47%) than in the ALN group (41.67%) (p<0.001). Patients receiving ALN/D5600 compared with ALN were at a significantlydecreased risk of vit-D insufficiency [odds ratio=0.02, 95% confidence interval(CI) 0.00-0.08]. In the ALN/D5600 group, significant increases in serum 25(OH) D were observed at weeks 8 (9.60 ng/mL) and 16 (11.41 ng/mL), where as a significant decrease was recorded in the ALN group at week 16 (-1.61 ng/mL). By multiple regression analysis, major determinants of increases in serum 25(OH) lumDwere ALN/D5600 administration, seasonal variation, and baseline 25(OH)D. The least squares mean percent change from baseline in serum PTH in the ALN/D5600 group (8.17%) was lower than that in the ALN group (29.98%) (p=0.0091). There was no significant difference between treatment groups in neuromuscular function. Overall safety was similar between groups. In conclusion, the administrationof 5600 IU vit-D in the ALN/D5600 group improved vit-D status and reduced the magnitude of PTH increase without significant side-effects after 16 weeks in Korean osteoporotic patients.
Abstract
Vitamin D (vit-D) is essential for bone health, although many osteoporosis patients have low levels of 25-hydroxy-vit-D [25(OH)D]. This randomized, open-label study compared the effects of once weekly alendronate 70 mg containing 5600 IU vit-D3 (ALN/D5600) to alendronate 70 mg without additional vit-D (ALN) on the percent of patients with vit-D insufficiency [25(OH)D <15 ng/mL, primary endpoint]and serum parathyroid hormone (PTH, secondary endpoint) levels in postmenopausal,osteoporotic Korean women. Neuromuscular function was also measured. A total of 268 subjects were randomized. Overall, 35% of patients had vit-D insufficiency at baseline. After 16-weeks, there were fewer patients with vit-D insufficiencyin the ALN/D5600 group (1.47%) than in the ALN group (41.67%) (p<0.001). Patients receiving ALN/D5600 compared with ALN were at a significantlydecreased risk of vit-D insufficiency [odds ratio=0.02, 95% confidence interval(CI) 0.00-0.08]. In the ALN/D5600 group, significant increases in serum 25(OH) D were observed at weeks 8 (9.60 ng/mL) and 16 (11.41 ng/mL), where as a significant decrease was recorded in the ALN group at week 16 (-1.61 ng/mL). By multiple regression analysis, major determinants of increases in serum 25(OH) lumDwere ALN/D5600 administration, seasonal variation, and baseline 25(OH)D. The least squares mean percent change from baseline in serum PTH in the ALN/D5600 group (8.17%) was lower than that in the ALN group (29.98%) (p=0.0091). There was no significant difference between treatment groups in neuromuscular function. Overall safety was similar between groups. In conclusion, the administrationof 5600 IU vit-D in the ALN/D5600 group improved vit-D status and reduced the magnitude of PTH increase without significant side-effects after 16 weeks in Korean osteoporotic patients.
참고문헌 (29)
- Center JR, "Mortality after all major types of osteoporotic fracture in men and women: an observational study", Lancet, 353, pp.878~882 (1999)
- Johnell O, "An estimate of the worldwide prevalence and disability associated with osteoporotic fractures", Osteoporos Int, 17, pp.1726~1733 (2006)
- Shi N, "Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures", Bone, 45, pp.1084~1090 (2009)
- 장숙랑, "춘천지역 폐경 후 여성의 골다공증 유병률과 관련 요인 : 한림노년연구", 예방의학회지, 39(5), pp.389~396 (2006), 대한예방의학회
- 정종관, "Fracture Incidence and Risk of Osteoporosis in Female Type 2 Diabetic Patients in Korea", Diabetes and Metabolism Journal, 36(2), pp.144~150 (2012), 대한당뇨병학회[DOI]
- 이상호, "Subsequent Hip Fracture in Osteoporotic Hip Fracture Patients", Yonsei Medical Journal, 53(5), pp.1005~1009 (2012), 연세대학교의과대학[DOI]
- Shin CS, "Prevalence and risk factors of osteoporosis in Korea: A community-based cohort study with lumbar spine and hip bone mineral density", BONE, 47, pp.378~387 (2010), ELSEVIER SCIENCE INC
- Holick MF, "Vitamin D deficiency: a worldwide problem with health consequences", Am J Clin Nutr, 87, pp.1080S~1086S (2008)
- Adami S, "Vitamin D status and response to treatment in post-menopausal osteoporosis", Osteoporos Int, 20, pp.239~244 (2009)
- 구지훈, "The Effects of Combined Treatment of Alendronate Plus Active or Plain Vitamin D on the Vitamin D Metabolism and Bone Turnover Markers in Patients with Osteoporosis", Endocrinology and Metabolism, 25(4), pp.305~309 (2010), 대한내분비학회
- Bischoff-Ferrari HA, "Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials", JAMA, 293, pp.2257~2264 (2005)
- Pfeifer M, "Vitamin D and muscle function", Osteoporos Int, 13, pp.187~194 (2002)
- Holick MF, "Vitamin D deficiency", N Engl J Med, 357, pp.266~281 (2007)
- Holick MF, "Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease", Am J Clin Nutr, 80(6 Suppl), pp.1678S~1688S (2004)
- Lim SK, "Vitamin D inadequacy in postmenopausal women in Eastern Asia", Curr Med Res Opin, 24, pp.99~106 (2008)
- Rizzoli R, "Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study", Int J Clin Pract, 60, pp.1013~1019 (2006)
- Recker R, "Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial", Curr Med Res Opin, 22, pp.1745~1755 (2006)
- National Osteoporosis Foundation, "Physician’s guide to prevention and treatment of osteoporosis. 2nd ed" (2003), National Osteoporosis Foundation
- Subcommittee on Interpretation, Uses of Dietary Reference Intakes. Dietary reference intakes. a report of the Subcommittee on Interpretation and Uses of Dietary Reference Intakes and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Applications in dietary assessment, "Institute of Medicine (U.S.)", National Academy Press, ~ (2001)
- Guralnik JM, "Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability", N Engl J Med, 332, pp.556~561 (1995)
- Guralnik JM, "A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission", J Gerontol, 49, pp.M85~M94 (1994)
- DeLuca HF, "Overview of general physiologic features and functions of vitamin D", Am J Clin Nutr, 80(6 Suppl), pp.1689S~1696S (2004)
- Holick MF, "High prevalence of vitamin D inadequacy and implications for health", Mayo Clin Proc, 81, pp.353~373 (2006)
- van Etten E, "1,25-dihydroxycholecalciferol: endocrinology meets the immune system", Proc Nutr Soc, 61, pp.375~380 (2002)
- Lips P, "The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects", J Clin Endocrinol Metab, 67, pp.644~650 (1988)
- Drake MT, "Bisphosphonates: mechanism of action and role in clinical practice", Mayo Clin Proc, 83, pp.1032~1045 (2008)
- Vasikaran SD, "Bisphosphonates: an overview with special reference to alendronate", Ann Clin Biochem, 38(Pt 6), pp.608~623 (2001)
- Horwitz MJ, "Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D", J Bone Miner Res, 20, pp.1792~1803 (2005)
- Wang YH, "Comparison of the action of transient and continuous PTH on primary osteoblast cultures expressing differentiation stage-specific GFP", J Bone Miner Res, 20, pp.5~14 (2005)